INTRODUCTION

In this case report, we present a 36-year-old woman with neck follicular dendritic cell sarcoma (FDCS) and pulmonary metastasis that was offered chemotherapy with gemcitabine and docetaxel regimen to which she responded dramatically and has remained disease free after 5 years of follow-up.

Follicular dendritic cell sarcoma is a rare tumor classified under WHO classification of histiocytic and dendritic cell neoplasms that was first defined by Monda et al in 1986. About one third of cases involve nodal sites, especially cervical lymph nodes, while 58% of cases have been reported to involve extranodal sites like liver, lung, tonsil, and spleen. It usually affects young to middle-aged adults (mean age of 44 years) with an almost equal incidence in both sexes.

Follicular dendritic cell sarcoma usually presents with an indolent and slowly growing, asymptomatic neck swelling. Only a small number of patients with abdominal disease experience systemic symptoms like fever, fatigue, and night sweats. The inflammatory pseudotumor-like variant of the disease is associated with Epstein-Barr virus and selectively involves liver and spleen and causes systemic symptoms and has a predilection toward female gender. Follicular dendritic cell sarcoma is associated with Castleman’s disease, myasthenia gravis, and paraneoplastic pemphigus. Diagnosis of FDCS is difficult, and in some instances, misdiagnosis with other malignancies has been reported.

CASE HISTORY

Here, we present a case of a 36-year-old woman who had initially presented with the complaint of unilateral left side neck swelling when she was 19 years old. On neck CT scan, she was found to have a 3 cm nodal neck mass for which she underwent surgery and lymph node dissection and was initially diagnosed with malignant fibrous histiocytoma. After surgery, she abandoned any other therapy and refused follow-up until 6 years later when her neck bulging recurred. The patient was referred to a surgeon for re-resection of the neck mass. The resected tumor was sent to a national specialty pathology center, and this time a diagnosis of follicular dendritic cell sarcoma was made. Again the patient refused any further therapy but came back with second recurrence of...
the tumor on the left side of her neck 3 years later. Local re-
section of the tumor and the lymph nodes and also superficial
parotidectomy on the left side showed no tumoral extension
to the parotid gland or deeper structures of the neck, but with
the same pathological diagnosis as before. This time with
the aim of maintaining a better local control, she received 30
fractions of adjuvant radiotherapy to a total cumulative dose
of 60 Grays over 6 weeks and was followed up in frequent
intervals for any signs of local or distant recurrences. Three
years later on follow-up when she was 31 years old, lung
metastases were detected on imaging. There were multiple
metastatic nodules on both lungs, the largest of them being a
33 \times 28 \text{mm} \text{nodule in right middle lobe which was selected}
for CT guided biopsy. Also, a large supraclavicular lymph
node on the left side was detected (24 \times 22 \text{mm}). The biopsy
of the lung nodule confirmed that it was pathologically simi-
lar to the previous neck mass; however, fine-needle aspiration
of the supraclavicular lymph node did not reveal malignant
cells in the aspirate. The patient was offered chemotherapy
and received 6 courses of gemcitabine plus docetaxel in
3-week intervals. She received gemcitabine in a fixed-dose
rate 900 \text{mg/m}^2 \text{intravenous infusion during 90 minutes on
days 1 and 8, with docetaxel 100 \text{mg/m}^2 \text{intravenously dur-
ing 60 minutes on day 8, every 21 days. In follow-up with
CT scan 6 months later, the metastatic nodules had shrinked
significantly and remained stable (Figure 1). The patient gave
birth to her first child 2 years after chemotherapy, and no new
metastases have been detected so far in the last 5 years.

3  |  CYTOLOGIC FINDINGS

Microscopic examination of the samples obtained through
primary neck mass excision and the subsequent recurrences,
indicated proliferation of spindle-shaped or ovoid cells con-
forming whorls and fascicles with prominent nucleoli and
vesiculated nuclei, and small amount of mitosis. Small, scat-
tered lymphocytes were seen among tumoral cells (Figures 2
and 3).

Frequently, residues of lymphoid tissue indicating lymph
nodes could be seen in the periphery of tumoral nodules. Also,
oneoplastic invasion could be seen in the vicinity of
skeletal muscles. However, no invasion to the skin was seen.
Immunohistochemistry examination on received samples
showed positive CD21, and CD23, negative S100, and nega-
tive stainings for LCA and CD68. IHC staining for HMB45,
CD1A, CD3, CD8, CD57, CK, smooth muscle antigen
(SMA), and α1 antitrypsin were all negative, and Ki67 posi-
tivity was 30%. (Figures 4 and 5).

Also, the CT-guided biopsy of the lung metastasis had
microscopic views similar to the above-mentioned specimen
from primary neck lesion and the recurrences.

4  |  DISCUSSION

Follicular dendritic cell sarcoma is composed of uniform,
spindle or ovoid cells, with eosinophilic cytoplasm and nu-
clei with a vesicular chromatin pattern, nuclear pseudoinclu-
sions, and prominent nucleoli, and these neoplastic cells are
usually arranged in fascicular, somewhat syncytial sheets,
with whorled or storiform patterns often with intermixed,
small lymphocytes.4,7

In IHC studies, FDCS cells commonly stain positive for
CD21, CD23, CD35, clusterin, γ-synuclein, vimentin, fas-
cin, desmoplakin, EGFR, HLA-DR, and Podoplanin (D2-40).
Staining for CD1a, lysozyme, myeloperoxidase, CD34, CD3,
CD79a, CD30, HMB-45, desmin, and high-molecular-weight
cytokeratins is negative. It is variably positive for epithelial
membrane antigen, S100, and CD68, which can cause diagnos-
tic difficulties and Ki-67 labeling ranges from 1% to 25%.4,8,9

Treatment for FDCS consists mainly of local control by
surgery. However, more aggressive treatment in lesions with
recurrences has been tried by other specialists including che-
motherapy and radiotherapy. As previously stated, the present
case received adjuvant radiotherapy after second recurrence
in her neck in order to lengthen her disease-free survival.

Due to the rarity of FDCS, there is no common consen-
sus on chemotherapy regimens but different regimens have
been used10 such as CHOP (cyclophosphamide, vincristine,
doxorubicin, prednisolone), and ICE (ifosfamide, carbopla-
tin, etoposide). These regimens have been used successfully
to treat lymph node malignancies; however, due to the mes-
enchymal and vascular stromal nature of FDCS rather than its

\textbf{FIGURE 1} Axial CT scan
views showing pulmonary metastasis
before (33 \times 28 \text{mm}) and 6 mo after
(13 \times 9 \text{mm}) chemotherapy with
gemcitabine + docetaxel
being hematopoietic, others have used regimens most effective on soft tissue sarcomas like gemcitabine and docetaxel combination with comparable success in the management of local and metastatic FDCS. Considering the patient’s preferences regarding the higher nonhematologic toxicities of doxorubicin-containing regimens compared with gemcitabine and docetaxel combination, the latter chemotherapy regimen was prescribed for her.

In the present case, we used a combination of gemcitabine and docetaxel after confirmation of lung metastasis for 6 cycles and after 6 months, significant shrinkage of lung metastasis was observed (33 × 28 mm to 13 × 9 mm).

FDCS usually is a slowly progressive neoplasm with multiple recurrences after local control of the disease. In a study by Saygin et al, 2-year survival rates for early, locally advanced, and distant metastatic diseases were 82.4%, 80%, and 42.8%, respectively.

In another study by Jain et al on 66 patients with FDCS, the median PFS, and OS times were 21 months and 47 months, respectively, and extranodal disease and bulky or intra-abdominal disease at presentation was associated with a poor prognosis. In another study by Shimono et al, all cases with inflammatory pseudotumor-like variant of FDCS survived after splenectomy for their splenic lesions without any further therapy; however, 71.4% of patients with typical FDCS died because of their disease in the follow-up time (median of 20 months).
We have detected only one case of FDCS in the literature that has had a history of 27 years of follow-up since the first diagnosis and at this time the patient had developed pulmonary metastasis.16

To sum it up, FDCS is a slowly progressive disease that if controlled appropriately by surgery, relatively acceptable survival can be expected for patients; however, after developing metastasis, prognosis declines significantly.

Our patient got metastases to her lungs 12 years after the first diagnosis of her disease, and in this period, she experienced regional recurrences twice. Her lung metastasis was treated with gemcitabine plus docetaxel chemotherapy and showed significant response to this regimen. There are very few cases reported in the literature that have used this regimen for metastasis treatment in patients with FDCS.

At the time of this writing which is 5 years after our patient getting metastatic, she is still alive without any significant morbidity.

ACKNOWLEDGMENTS
The authors would like to thank Cancer Institute Pathology Department at Imam Khomeini Hospital Complex for their help with providing access to microscopic views of previous surgical sections of the reported case.

CONFLICT OF INTEREST
None declared.

AUTHOR CONTRIBUTIONS
EE: He is the physician in charge of the patient's treatment. He gathered all required data including pathologic and radiologic documents. He contributed significantly in the scientific writing and editing of the manuscript. KK: He contributed in writing of the manuscript, data gathering, literature review, and scientific editing of the manuscript.

ETHICAL APPROVAL
This article was approved by the Imam Khomeini Hospital Complex ethics committee.

ORCID
Kasra Kolahdouzan https://orcid.org/0000-0003-1522-5619

REFERENCES
1. Swerdlow SHCE, Harris NL, Jaffe ES. WHO classification of tumors of haematopoietic and lymphoid tissues. 4th edition. 2017.
2. Monda L, Warnke R, Rosai J. A primary lymph node malignancy with features suggestive of dendritic reticulum cell differentiation. A report of 4 cases. Am J Pathol. 1986;122(3):562-572.
3. Saygin C, Uzunaslan D, Ozgorulu M, Senocak M, Tuzuner N. Dendritic cell sarcoma: a pooled analysis including 462 cases with presentation of our case series. Crit Rev Oncol Hematol. 2013;82(2):253-271. https://doi.org/10.1016/j.critrevonc.2013.05.006
4. Wu A, Pullar kat S. Follicular Dendritic Cell Sarcoma. Arch Pathol Lab Med. 2016;140(2):186-190. https://doi.org/10.5858/arpa.2014-0374-RS
5. Hsu C, Vega F, Grimes LM, Hunt KK. Follicular dendritic cell sarcoma and associated Myasthenia Gravis: true, true, related? J Clin Oncol. 2011;29(13):e369-e371. https://doi.org/10.1200/JCO.2010.32.7932
6. Su Z, Liu G, Liu J, et al. Paraneoplastic pemphigus associated with follicular dendritic cell sarcoma: report of a case and review of literature. Int J Clin Exp Pathol. 2015;8(10):11983-11994.
7. Chen T, Gopal P. Follicular dendritic cell sarcoma. Arch Pathol Lab Med. 2017;141(4):596-599. https://doi.org/10.5858/arpa.2016-0126-RS
8. Dutta A, Arun P, Roy P, Arun I. Cytological diagnosis of follicular dendritic cell sarcoma: a case report and review of literature. Cytopathology. 2018;29(5):461-467. https://doi.org/10.1111/cyt.12558
9. Pizzi M, Ludwig K, Palazzolo G, Busatto G, Rettore C, Altavilla G. Cervical follicular dendritic cell sarcoma: a case report and review of the literature. Int J Immunopathol Pharmacol. 2011;24(2):539-544. https://doi.org/10.1177/039463201102400231
10. Liberale G, Keriakos K, Azerad M, De Saint AN, El Nakadi I. Intrapitoneal follicular dendritic cell sarcoma: role of chemotherapy and bone marrow allotransplantation in locally advanced disease? Clin Med Insights Oncol. 2015;9:9-13. https://doi.org/10.4137/CMI.S12601
11. Pang J, Myldzar WK, Gooi Z, et al. Follicular dendritic cell sarcoma of the head and neck: case report, literature review, and pooled analysis of 97 cases. Head Neck. 2016;38(S1):E2241-E2249
12. Conry RM. Response of follicular dendritic cell sarcoma to gemcitabine and docetaxel: report of two cases and literature review. Clin Sarcoma Res. 2014;4:6.
13. Gupta AM, Goel M, Sahay A, Janjal SP, Patkar S. Role of adjuvant chemotherapy in extranodal follicular dendritic cell sarcoma. ACG Case Rep J. 2019;6(3):1-4. https://doi.org/10.14309/crj.0000000000000008
14. Jain P, Milgrom SA, Patel KP, et al. Characteristics, management, and outcomes of patients with follicular dendritic cell sarcoma. Br J Haematol. 2017;178(3):403-412. https://doi.org/10.1111/bjh.14672
15. Shimono J, Miyoshi H, Arakawa F, et al. Prognostic factors for histiocytic and dendritic cell neoplasms. Oncotarget. 2017;8(58):98723-98732. https://doi.org/10.18632/oncotarget.21920
16. Choi PC, To KF, Lai FM, Lee TW, Yim AP, Chan JK. Follicular dendritic cell sarcoma of the neck: report of two cases complicated by pulmonary metastases. Cancer. 2000;89(3):664-672.

How to cite this article: Esmati E, Kolahdouzan K. Metastatic follicular dendritic cell sarcoma treated with gemcitabine plus docetaxel with an outstanding survival: A case report and review of literature. Clin Case Rep. 2021;9:473–476. https://doi.org/10.1002/ccr3.3560